We are live on
!
Find out more
BGA
Belmont Global Advisors Portfolio holdings
AUM
$106M
1-Year Est. Return
2.89%
This Fund
S&P 500
This Quarter
Est. Return
+8.71%
1 Year Est. Return
-2.89%
3 Year Est. Return
+81.05%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$106M
AUM Growth
+$1.54M
(+1.5%)
Cap. Flow
-$4.07M
Cap. Flow
% of AUM
-3.85%
Top 10 Holdings %
Top 10 Hldgs %
66.08%
Holding
96
New
32
Increased
14
Reduced
12
Closed
27
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alaunos Therapeutics
TCRT
|
+$2.18M |
| 2 |
IMPV
Imperva, Inc.
IMPV
|
+$1.32M |
| 3 |
BDSI
BioDelivery Sciences International, Inc.
BDSI
|
+$1.08M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$1.06M |
| 5 |
Build-A-Bear
BBW
|
+$979K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Acadia Pharmaceuticals
ACAD
|
+$1.29M |
| 2 |
Home Depot
HD
|
+$1.28M |
| 3 |
Palo Alto Networks
PANW
|
+$1.04M |
| 4 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
+$960K |
| 5 |
Check Point Software Technologies
CHKP
|
+$797K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 26.08% |
| 2 | Technology | 5.99% |
| 3 | Consumer Discretionary | 3.69% |
| 4 | Industrials | 2.56% |
| 5 | Consumer Staples | 2.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CALL
Alaunos Therapeutics
TCRT
$4.93M
| $15.7M | 14.83% |
18,561
+2,528
| +16% | +$2.03M |
|
2
CALL
Precigen
PGEN
$1.8B
| $12.7M | 12.06% |
459,095
-20,180
| -4% | -$534K |
|
|
3
Alaunos Therapeutics
TCRT
$4.93M
| $12.5M | 11.85% |
14,835
+2,715
| +22% | +$2.18M |
|
4
PUT
Invesco QQQ Trust
QQQ
$466B
| $11.9M | 11.23% |
+100,000
| New | +$11.5M |
|
|
5
Precigen
PGEN
$1.8B
| $8.42M | 7.97% |
303,255
+20,180
| +7% | +$534K |
|
|
MNDT
6
CALL
DELISTED
Mandiant, Inc. Common Stock
MNDT
| $2.21M | 2.09% |
+150,000
| New | +$2.3M |
|
|
VBTX
7
DELISTED
Veritex Holdings
VBTX
| $1.66M | 1.57% |
95,404
+1,175
| +1% | +$20K |
|
8
Fortress Biotech
FBIO
$115M
| $1.62M | 1.53% |
36,333
-334
| -0.9% | -$14.2K |
|
|
9
CALL
Acadia Pharmaceuticals
ACAD
$4.32B
| $1.59M | 1.51% |
50,000
-100,000
| -67% | -$3.39M |
|
|
IMPV
10
DELISTED
Imperva, Inc.
IMPV
| $1.53M | 1.45% |
+28,500
| New | +$1.32M |
|
|
SGYP
11
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $1.49M | 1.41% |
270,000
-115,000
| -30% | -$538K |
|
12
Amazon
AMZN
$2.7T
| $1.26M | 1.19% |
30,160
| – | – |
|
|
AIRM
13
CALL
DELISTED
Air Methods Corp
AIRM
| $1.26M | 1.19% |
+40,000
| New | +$1.36M |
|
|
MNDT
14
DELISTED
Mandiant, Inc. Common Stock
MNDT
| $1.19M | 1.13% |
81,000
+21,000
| +35% | +$323K |
|
15
SPDR Gold Trust
GLD
$129B
| $1.18M | 1.12% |
9,265
+7,415
| +401% | +$944K |
|
16
Microsoft
MSFT
$2.99T
| $1.16M | 1.09% |
20,055
| – | – |
|
|
BDSI
17
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $1.15M | 1.09% |
+425,000
| New | +$1.08M |
|
18
CALL
Cytokinetics
CYTK
$10.9B
| $1.1M | 1.04% |
+120,000
| New | +$1.25M |
|
|
SGYP
19
CALL
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $1.1M | 1.04% |
+200,000
| New | +$936K |
|
20
BlackRock Core Bond Trust
BHK
$657M
| $1.07M | 1.01% |
75,069
+1,455
| +2% | +$20.5K |
|
21
LSB Industries
LXU
$817M
| $1.03M | 0.97% |
156,000
+104,000
| +200% | +$884K |
|
|
22
Alnylam Pharmaceuticals
ALNY
$36.5B
| $1.02M | 0.96% |
+15,000
| New | +$1.06M |
|
23
Meta Platforms (Facebook)
META
$1.65T
| $1.01M | 0.95% |
7,860
+160
| +2% | +$19.9K |
|
24
O'Reilly Automotive
ORLY
$70.3B
| $984K | 0.93% |
52,680
| – | – |
|
25
OneSpan
OSPN
$572M
| $880K | 0.83% |
+50,000
| New | +$879K |
|
Similar funds
LOT
EC
SAMNY
DCMM
PCM
SVGI
EDRM
EDRAML
Belmont Global Advisors's Q3 2016 Portfolio in Review
As of Q3 2016, Belmont Global Advisors held 96 positions worth $106M, up 1.5% from $104M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Belmont Global Advisors withdrew a net $4.07M in Q3 2016, closing 27 positions and reducing 12 holdings. Its most notable exit was Acadia Pharmaceuticals, an estimated $1.29M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 26% of assets, up from 23% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Belmont Global Advisors opened a new position in Imperva, Inc. worth $1.53M.
- Belmont Global Advisors's largest Q3 2016 buy was Imperva, Inc.: 28,500 shares worth $1.53M.
- Belmont Global Advisors added most to Alaunos Therapeutics in Q3 2016, an estimated $2.18M increase.
- Belmont Global Advisors's biggest Q3 2016 reduction was Fate Therapeutics, cutting an estimated $607K.
- Belmont Global Advisors fully exited Acadia Pharmaceuticals in Q3 2016, selling an estimated $1.29M.
- Belmont Global Advisors's ten largest holdings make up 66% of its $106M portfolio in Q3 2016.
- Belmont Global Advisors opened 32 new positions and closed 27 in Q3 2016.
- Belmont Global Advisors's portfolio value rose 1.5% quarter-over-quarter to $106M.
Based on Belmont Global Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.